Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer
This trial is active, not recruiting.
|Treatment||laboratory biomarker analysis|
|Sponsor||Alliance for Clinical Trials in Oncology|
|Collaborator||National Cancer Institute (NCI)|
|Start date||October 2011|
|End date||January 2100|
|Trial size||261 participants|
|Trial identifier||NCT01415739, CALGB-151102, CDR0000706383, NCI-2011-02977|
This research studies protein in tumor samples from patients with non-small cell lung cancer. Finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient has and plan better treatment.
Previously collected tissue samples are analyzed via H&E staining and IHC.
Validation of a novel 4-protein signature's ability to subtype NSCLC
time frame: 1 month
NSCLC misclassification rate
time frame: 1 month
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients must have been registered on CALGB-9761 - Stage I disease - Treatment-naive patients - A representative paraffin block of the primary tumor must be available from patients on CALGB-9761 and submitted to the CALGB Pathology Coordinating Office - A separate consent form is not required for this study, as permission for research to be performed on the tissue blocks is included in the consent form for CALGB 9761 - Institutional review board (IRB) review and approval at the institution where the laboratory work will be performed is required
|Official title||Evaluation of a Novel Molecular NSCLC Classification System|
|Description||PRIMARY OBJECTIVES: I. To validate a novel 4-protein signature's ability to subtype non-small cell lung cancer (NSCLC) in a treatment-naive, multi-institutional cohort, Cancer and Leukemia Group B (CALGB) 9761. SECONDARY OBJECTIVES: I. To estimate the NSCLC misclassification rate in a multi-institutional clinical-trial setting for stage 1 NSCLC (adenocarcinoma versus squamous cell). OUTLINE: Previously collected tissue samples are analyzed via hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC).|
Call for more information